These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 15226326

  • 1. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
    Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A, Spanish Breast Cancer Research Group.
    J Clin Oncol; 2004 Jul 01; 22(13):2587-93. PubMed ID: 15226326
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M, BIG 02-98 Collaborative Group.
    J Natl Cancer Inst; 2008 Jan 16; 100(2):121-33. PubMed ID: 18182617
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM, Smylie M, Mackey JR, Noel D, Paterson AH, al-Tweigeri T, Au D, Sansregret E, Delorme F, Riva A.
    Oncology (Williston Park); 1997 Aug 16; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
    Shamseddine AI, Otrock ZK, Khalifeh MJ, Yassine HR, Charafeddine M, Abdel-Khalek Z, Chehal A, Bitar N, Jalloul R, Dheiny M, Dandashi A, Wehbeh M, El-Saghir NS.
    Oncology; 2006 Aug 16; 70(5):330-8. PubMed ID: 17164589
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM.
    J Clin Oncol; 2005 Jul 01; 23(19):4265-74. PubMed ID: 15911866
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
    Mattioli R, Lippe P, Massacesi C, Cappelletti C, Nacciarriti D, Bisonni R, Graziano F, Menichetti ET, Imperatori L, Testa E, Laici G, Balletra A, Silva RR.
    Anticancer Res; 2004 Jul 01; 24(5B):3257-61. PubMed ID: 15510620
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.
    Clin Breast Cancer; 2002 Dec 01; 3(5):333-40. PubMed ID: 12533263
    [Abstract] [Full Text] [Related]

  • 13. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
    Stemmler J, Mair W, Stauch M, Papke J, Deutsch G, Abenhardt W, Dorn B, Kentenich C, Malekmohammadi M, Jackisch C, Leinung S, Brudler O, Vehling-Kaiser U, Stamp J, Heinemann V.
    Oncology; 2005 Dec 01; 68(1):71-8. PubMed ID: 15809523
    [Abstract] [Full Text] [Related]

  • 14. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
    Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS.
    Oncol Rep; 2005 Aug 01; 14(2):481-7. PubMed ID: 16012734
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.
    Cancer Chemother Pharmacol; 2010 Mar 01; 65(4):755-63. PubMed ID: 19669644
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
    Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P, TAX 306 Study Group.
    J Clin Oncol; 2003 Mar 15; 21(6):968-75. PubMed ID: 12637459
    [Abstract] [Full Text] [Related]

  • 17. Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
    Stemmler HJ, Harbeck N, Gröll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, Artmann A, Sommer H, Meerpohl HG, Kiechle M, Heinemann V.
    Oncology; 2010 Mar 15; 79(3-4):204-10. PubMed ID: 21358208
    [Abstract] [Full Text] [Related]

  • 18. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C, Dutch Community Setting Trial for the Clinical Trial Group.
    J Clin Oncol; 2005 Oct 01; 23(28):7081-8. PubMed ID: 16192591
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW, Sohn JH, Choi HJ, Chang H, Park BW, Kim SI, Park S, Koo JS, Kim YT, Roh JK, Chung HC, Kim JH.
    Cancer Chemother Pharmacol; 2010 Aug 01; 66(3):425-31. PubMed ID: 20012956
    [Abstract] [Full Text] [Related]

  • 20. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
    Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR.
    J Clin Oncol; 2011 Oct 10; 29(29):3877-84. PubMed ID: 21911726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.